首页|期刊导航|Oncology Research|The Construction and Preclinical Evaluation of Antitumor Activity of a Novel MIgG-OXA ADC in Lung Adenocarcinoma

The Construction and Preclinical Evaluation of Antitumor Activity of a Novel MIgG-OXA ADC in Lung AdenocarcinomaOA

中文摘要

Background:The melanoma-associated antigen-A1(MAGE-A1)demonstrates tumor-restricted expression patterns in diverse malignancies,positioning it as an attractive therapeutic target.This investigation aimed to engineer and validate a novel antibody-drug conjugate with oxaliplatin targeting MAGE-Al(MIg-OXA),a novel antibody-drug conjugate targeting MAGE-A1,while assessing its therapeutic potential against MAGE-A1-expressing lung adenocarcinoma through both cellular and animal models.Methods:We generated a MAGE-A1-specific immunoglobulin G(IgG)antibody(MIgG)and subsequently conjugated it with oxaliplatin(OXA)to produce MIgG-OXA.The conjugate’s binding specificity and cellular uptake were verified through cell-based enzyme-linked immunosorbent assay(ELISA),flow cytometric analysis,and immunofluorescence microscopy.Functional assessments included Cell Counting Kit-8(CCK-8)viability assays,transwell migration studies,apoptosis detection,and antibody-dependent cell-mediated cytotoxicity(ADCC)evaluation to determine anti-neoplastic activity in cultured cells.Therapeutic efficacy in living organisms was examined using lung adenocarcinoma(LUAD)xenograft-bearing athymic mice.Results:Our data confirmed successful synthesis and validation of MIgG-OXA,which demonstrated selective recognition of MAGE-A1-expressing LUAD cell populations and facilitated controlled OXA release.When compared to unconjugated OXA,MIgG-OXA displayed enhanced tumor suppression in both cultured LUAD cells and transplanted tumor models.Conclusion:These findings collectively indicate that MIgG-OXA holds substantial promise as a precision therapeutic approach for patients harboring MAGE-A1-positive LUAD.

Haijun Sun;Wenyue Yan;Zhanyu Li;Qintian Li;Qilong Du;Li Xu;Wanwei Cao;Junrong Yang;Xilan Yang;Jun Chen;Yuan Mao;Wen Huang

Department of Thoracic Surgery,The First People’s Hospital of Lianyungang,The First Affiliated Hospital of Kangda College of Nanjing Medical University,Lianyungang,ChinaDepartment of Geriatric Palliative Care,Thoracoabdominal Oncology Center,The Fourth Affiliated Hospital of Nanjing Medical University,Nanjing,ChinaDepartment of Pathology,the Fifth Affiliated Hospital,Sun Yat-sen University,Zhuhai,ChinaDepartment of Geriatric Oncology,Thoracoabdominal Oncology Center,The Fourth Affiliated Hospital of Nanjing Medical University,Nanjing,ChinaDepartment of Geriatric Oncology,Thoracoabdominal Oncology Center,The Fourth Affiliated Hospital of Nanjing Medical University,Nanjing,ChinaDepartment of Pathology,Jiangsu Cancer Hospital,Affiliated Cancer Hospital of Nanjing Medical University,Nanjing,ChinaDepartment of Pathology,the Fifth Affiliated Hospital,Sun Yat-sen University,Zhuhai,ChinaDepartment of Pathology,The Fourth Affiliated Hospital of Nanjing Medical University,Nanjing,ChinaDepartment of Geriatric Palliative Care,Thoracoabdominal Oncology Center,The Fourth Affiliated Hospital of Nanjing Medical University,Nanjing,ChinaDepartment of Respiratory Medicine,Jiangsu Province Geriatric Hospital,Geriatric Hospital of Nanjing Medical University,Nanjing,ChinaDepartment of Hematology and Oncology,Jiangsu Province Geriatric Hospital,Geriatric Hospital of Nanjing Medical University,Nanjing,ChinaDepartment of Geriatric Oncology,Thoracoabdominal Oncology Center,The Fourth Affiliated Hospital of Nanjing Medical University,Nanjing,China

医药卫生

Melanoma-associated antigen-A1(MAGE-A1)immunoglobulin G(IgG)oxaliplatin(OXA)antibodydrug conjugates(ADCs)

《Oncology Research》 2026 (8)

P.452-470,19

supported by the grants from the National Natural Science Foundation(82073389 and 82473332 to Yuan Mao)Jiangsu Province“333 Project”Research Program((2022)3-1-327 to Yuan Mao)the Natural Science Foundation of Jiangsu Province(BK20241750 to Yuan Mao)Nanjing Jiangbei New Area Key Research and Development Program(ZDYF202502 to Wen Huang)Lianyungang Health General Science and Technology Program(202510 to Haijun Sun).

10.32604/or.2026.080413

评论